CY1113115T1 - Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες - Google Patents

Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες

Info

Publication number
CY1113115T1
CY1113115T1 CY20121100268T CY121100268T CY1113115T1 CY 1113115 T1 CY1113115 T1 CY 1113115T1 CY 20121100268 T CY20121100268 T CY 20121100268T CY 121100268 T CY121100268 T CY 121100268T CY 1113115 T1 CY1113115 T1 CY 1113115T1
Authority
CY
Cyprus
Prior art keywords
seq
hiv fusion
peptides
biological properties
fusion inhibitors
Prior art date
Application number
CY20121100268T
Other languages
Greek (el)
English (en)
Inventor
John Dwyer
Brian L Bray
Stephen E Schneider
Huyi Zhang
Nicolai A Tvermoes
Barbara E Johnston
Paul E Friedrich
Original Assignee
Synageva Biopharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp. filed Critical Synageva Biopharma Corp.
Publication of CY1113115T1 publication Critical patent/CY1113115T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20121100268T 2006-02-02 2012-03-14 Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες CY1113115T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76467406P 2006-02-02 2006-02-02
EP07749903A EP1989220B1 (en) 2006-02-02 2007-02-02 Hiv fusion inhibitor peptides with improved biological properties

Publications (1)

Publication Number Publication Date
CY1113115T1 true CY1113115T1 (el) 2016-04-13

Family

ID=38437849

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100268T CY1113115T1 (el) 2006-02-02 2012-03-14 Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες

Country Status (15)

Country Link
US (3) US7456251B2 (enExample)
EP (1) EP1989220B1 (enExample)
JP (1) JP4682251B2 (enExample)
CN (1) CN101415723B (enExample)
AR (2) AR059300A1 (enExample)
AT (1) ATE537183T1 (enExample)
AU (1) AU2007218025A1 (enExample)
CA (1) CA2651793C (enExample)
CY (1) CY1113115T1 (enExample)
DK (1) DK1989220T3 (enExample)
ES (1) ES2381631T3 (enExample)
NZ (1) NZ570300A (enExample)
PT (1) PT1989220E (enExample)
TW (1) TWI341844B (enExample)
WO (1) WO2007097903A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1989220B1 (en) 2006-02-02 2011-12-14 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
US8828931B2 (en) * 2008-05-28 2014-09-09 New York Blood Center, Inc. Bifunctional molecules for inhibiting HIV entry
US7919101B2 (en) 2008-08-13 2011-04-05 New York Blood Center Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors
WO2010045613A1 (en) * 2008-10-16 2010-04-22 New York Blood Center Immunoenhancer-linked oligomeric hiv vaccines
WO2010047826A2 (en) * 2008-10-24 2010-04-29 Trimeris, Inc. Dosing regimens and dosage formulations of an antiviral peptide therapeutic
CA2751865A1 (en) * 2009-02-09 2010-08-12 New York Blood Center, Inc. Trimeric hiv fusion inhibitors for treating or preventing hiv infection
CA2794632A1 (en) 2010-05-03 2011-11-10 New York Blood Center, Inc. Bifunctional molecules for inactivating hiv and blocking hiv entry
RU2014129907A (ru) * 2011-12-19 2016-02-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Ингибиторы слияния hiv с мембраной
US20150045291A1 (en) 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CN103724404B (zh) * 2013-12-08 2016-11-02 北京工业大学 抑制hiv病毒与宿主细胞融合的非对映体多肽及其用途
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
CN1030256A (zh) * 1987-06-29 1989-01-11 日清食品株式会社 检测和治疗人类免疫缺陷病毒的方法和物质
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
AU2791792A (en) 1991-10-04 1993-05-03 Robert H. Cornett Approaching emergency vehicle warning system
ES2139017T3 (es) 1992-07-20 2000-02-01 Univ Duke Compuestos que inhiben la replicacion del vih.
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5589167A (en) 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
CA2224008C (en) 1995-06-07 2009-08-18 Trimeris, Inc. The treatment of hiv and other viral infections using combinatorial therapy
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
WO1999033489A1 (fr) 1997-12-26 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales a liberation prolongee
JPH11209456A (ja) * 1998-01-29 1999-08-03 Hitachi Chem Co Ltd 印刷配線板用難燃性エポキシ樹脂組成物及びこれを用いたプリプレグ、金属箔張り積層板
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US7582301B1 (en) 1999-05-17 2009-09-01 Conjuchem Biotechnologies, Inc. Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
WO2001078683A2 (en) 2000-04-19 2001-10-25 Genentech, Inc. Sustained release formulations comprising growth hormone
ES2554106T3 (es) 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
CN1100564C (zh) 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
BRPI0418304A (pt) 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
CN101132812A (zh) 2004-03-15 2008-02-27 阿拉巴马耐科塔医药公司 Hiv进入抑制剂的聚合物基组合物和结合物
CA2556032A1 (en) * 2004-03-15 2005-09-29 Trimeris, Inc. Site-specific chemical modification of hiv gp41-derived peptides
EP1989220B1 (en) 2006-02-02 2011-12-14 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties

Also Published As

Publication number Publication date
WO2007097903A3 (en) 2008-05-22
TWI341844B (en) 2011-05-11
JP2009525051A (ja) 2009-07-09
US7456251B2 (en) 2008-11-25
CA2651793C (en) 2015-07-07
DK1989220T3 (da) 2012-04-02
TW200806687A (en) 2008-02-01
ATE537183T1 (de) 2011-12-15
JP4682251B2 (ja) 2011-05-11
EP1989220A4 (en) 2009-05-06
PT1989220E (pt) 2012-03-23
CN101415723A (zh) 2009-04-22
EP1989220A2 (en) 2008-11-12
WO2007097903A2 (en) 2007-08-30
US20090105143A1 (en) 2009-04-23
EP1989220B1 (en) 2011-12-14
NZ570300A (en) 2011-08-26
AR059300A1 (es) 2008-03-26
CN101415723B (zh) 2014-06-25
US20120040891A1 (en) 2012-02-16
ES2381631T3 (es) 2012-05-30
CA2651793A1 (en) 2007-08-30
US20070179278A1 (en) 2007-08-02
US8034899B2 (en) 2011-10-11
AU2007218025A1 (en) 2007-08-30
AR108277A2 (es) 2018-08-01

Similar Documents

Publication Publication Date Title
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
UA103882C2 (uk) Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
PE20161325A1 (es) L-asparaginasa tratada con peg
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
EA200900064A1 (ru) Ингибирование агрегации альфа-синуклеина
CO6241137A2 (es) Antagonistas ciclicos de peptido cxcr4
NZ607892A (en) Tfpi inhibitors and methods of use
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
MX2022001933A (es) Inhibidores de enzimas.
CY1112992T1 (el) Μεσο καλλιεργειας χωρις ορο για την παρασκευη ανασυνδυασμενων γοναδοτροπινων
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
BR0306928A (pt) Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой